Successful Pharma Facility Marketing
Shire plc. retained PharmBioSource, Inc. as its exclusive consultant to market and sell its 340,000 SF pharma / biotech manufacturing facility located in Krems, Austria.
Shire is a global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. The company’s products are available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics. As part of its manufacturing site network consolidation plan, Shire made the strategic decision to divest its pharma / biotech manufacturing site located near Vienna that it had acquired from Baxalta in 2015.
The facility represented an excellent opportunity for a buyer to acquire a significant utility-ready pharmaceutical and biotech manufacturing asset at a discount and with a significant reduction in time to market.
To assist Shire with its goal of divesting its Krems, Austria manufacturing site, PharmaBioSource engaged the pharmaceutical and biotech industry to market and sell the site to a strategic acquirer.
We utilized our technical expertise and extensive contacts within the Life Sciences Industry to identify a number of potential buyers for the Krems site.
Services provided by the PharmaBioSource team:
PharmaBioSource, Inc. solicited multiple offers for the Shire site and ultimately identified Merck Animal Health, the global animal health business unit of MSD, which offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services, as the acquirer. The transaction represented a significant value for Shire and the entire deal was completed in just 9 months.